Key Drivers
- Cash Surplus
- No Revenue
- Ongoing Burn
AIAI Summary
ANRO now screens as a well-funded, catalyst-driven biotech rather than a near-term financing risk, with ALTO-207's Phase 2b readout and the independent pramipexole validation offering real upside if human efficacy is reproducible, but after the recent rally the main action point is to watch whether upcoming data can justify further multiple expansion or trigger a sharp de-rating on disappointment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Surplus
- •No Revenue
- •Ongoing Burn
ANRO has an exceptionally strong cash-rich balance sheet and minimal leverage, but the lack of revenue, persistent losses, and ongoing cash burn make the current valuation hard to justify.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Profit-taking pullback
- •Mid-20s support
ANRO remains in a bullish medium-term uptrend over the last month, but after hitting $28.07 it has pulled back about 12%, making the $24.40–$24.90 support zone the key level to hold before another breakout attempt.
Pulled back about 12% from the late-June high of $28.07 after a sharp run-up
Sentiment & News
Key News Insights:
- •Independent trial
- •Anhedonia benefit
- •External validation
Independent, randomized, placebo-controlled PRIME-PRAXOL data published in Nature Medicine showed significant pramipexole benefit on anhedonia, adding encouraging external support for its potential in mood disorders.
This is a modestly positive read-through for Alto Neuroscience because it reinforces the therapeutic relevance of targeting anhedonia, though the evidence is indirect and comes from an outside study
Similar Companies in Healthcare
Other companies in the same sector with AI ratings